MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ATAI

ATAI

Atai Beckley Inc.

$4.67
-0.15
 (-3.01%)
Exchange:  NASDAQ
Market Cap:  1.717B
Shares Outstanding:  152.57M
Delayed data
Calculate ATAI Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Christian Angermayer
Full Time Employees:  99
Address: 
250 West 34th Street
New York
NY
10119
US
Website:  https://www.ataibeckley.com
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue3143084,089
Gross Profit-5-1653,077
EBITDA-125,152-102,218-98,749
Operating Income-125,471-102,691-99,761
Net Income-40,224-149,269-660,047

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets293,478159,387310,540
Total Liabilities49,16242,83388,539
Total Stockholders Equity242,962116,297221,874
Total Debt19,14224,7062,072
Cash and Cash Equivalents45,03417,50585,300

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-84,118-82,437-102,675
Capital Expenditure-590-95-901
Free Cash Flow-84,708-82,532-103,576
Net Income-40,224-150,049-660,047
Net Change in Cash-145,579-17,52957,795

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)294,299.094Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)540,874.011Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)377,021.002Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-540,874.011Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-294,299.094Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-377,021.002Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)29,795.857Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)65,239.177Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)41,686.563Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)39,760,410.242Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)73,073,186.445Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)50,936,309.404Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.180Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0.290Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.130Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)5Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)5Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
308000  ?P/S
 (TTM)
: 
478.15
?Net Income
 (TTM)
: 
-149269000  ?P/E
 (TTM)
: 
-1.55
?Enterprise Value
 (TTM)
: 
1.627B  ?EV/FCF
 (TTM)
: 
-13.88
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-3.66  ?ROIC
 (TTM)
: 
-0.53
?Net Debt
 (TTM)
: 
-47624000  ?Debt/Equity
 (TTM)
: 
0.01
?P/B
 (TTM)
: 
5.16  ?Current Ratio
 (TTM)
: 
10.02

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about ATAI valuation

Is Atai Beckley Inc. (ATAI) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Atai Beckley Inc. (ATAI) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ATAI a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ATAI trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ATAI’s P/E ratio?

You can see ATAI’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ATAI?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ATAI a good long-term investment?

Whether ATAI fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ATAI

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-3.01
MARKETSnap

Trading Metrics:

Open: 4.71   Previous Close: 4.81
Day Low: 4.46   Day High: 4.78
Year Low: 2   Year High: 6.75
Price Avg 50: 4.08   Price Avg 200: 4.31
Volume: 3.042M   Average Volume: 5.702M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

AtaiBeckley launches mental health patient impact grant program
28-05-2026 09:58
AtaiBeckley launches mental health patient impact grant program
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
27-05-2026 06:00
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says
13-05-2026 13:07
AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says
AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances
12-05-2026 09:25
AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
27-04-2026 04:05
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003
08-04-2026 08:43
AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read